Letter

Follow-up after breast cancer

National randomised controlled trial is needed

BMJ 2008; 336 doi: 10.1136/bmj.39500.469664.1F (Published 28 February 2008)
Cite this as: BMJ 2008;336:461.3

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Peter K Donnelly, consultant surgeon,
  2. Louise Hiller, senior research fellow in medical statistics,
  3. Janet A Dunn, head of cancer trials
  1. 1South Devon Healthcare NHS Foundation Trust, Torquay TQ2 7AA
  2. 2Warwick Medical School Clinical Trials Unit, University of Warwick, Coventry CV4 7AL
  1. peter.donnelly{at}nhs.net

    Dixon and Montgomery recommend that breast cancer follow-up be evidence based, flexible, and tailored to patients’ needs.1 Unfortunately neither their proposal to provide only annual clinical review for two years nor the 2002 guideline from the National Institute for Health and Clinical Excellence, which recommends hospital based follow-up for no longer than three years for asymptomatic patients, is evidence based. A recent Cochrane review showed a wide range of recommendations for follow-up practice and identified the urgent need for a large randomised controlled trial …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular